Women’s health therapeutics succeed or fail in the space between great science and executable regulation. JASTLabs has added depth across advisory and management functions precisely because our lead programs require credible oversight in CMC, clinical strategy, and interactions with health authorities.
New appointments strengthen our ability to translate formulation progress into an IND-aligned roadmap: clear manufacturing narratives, well-designed toxicology plans, and clinical protocols that reflect how women actually use medicines in daily life.
On the commercial side, we are preparing early for how differentiated products reach clinicians and patients—without jumping ahead of evidence. That discipline protects shareholders and patients alike: we intend to earn adoption through data, labeling, and access planning grounded in reality.
We welcome these leaders to JASTLabs and look forward to updating the market as their work translates into concrete milestones on our path toward FDA engagement and beyond.